Donate

On The Horizon- Coming Soon – Radium-223 (Alpharadin) A Bone Targeted Treatment for Advanced Prostate Cancer that Extends Life

At the recent European Multidisciplinary Cancer Congress in Stockholm, Dr Chris Parker from The Royal Marsden Hospital presented results of the phase 3 ALSYMPCA trial that showed both delayed time to first skeletal-related event (SRE) AND an overall survival (OS) benefit for those men with advanced prostate cancer taking radium-223 (Alpharadin). The real significance of [...]

Combining and Sequencing the New Prostate Cancer Drugs, Can It Improve Treatment Outcomes? – On the Horizon

There is good reason for guarded optimism among men with advanced prostate cancer. Over the last 2 years we have seen some significant movement with the development of new drugs and treatments for men with advanced prostate cancer. All of these drugs have demonstrated a survival advantage in their clinical trials. Each of the agents [...]

On the Horizon – Alpharadin (Radium-223)- A Long Survival Possibility for Men with Castrate Resistant Prostate Cancer

In 2007 a Norwegian cancer therapeutics company, Algeta, presented data from a phase II study that showed a remarkable two-year survival advantage with its investigational drug, Alpharadin (radium-223), when used as a as a treatment for castrate resistant prostate cancer (CRPC). […]

Additional Information On Yesterday’s Post About Alpharadin

Charles (Chuck) Maack, Prostate Cancer Advocate/Mentor from the Wichita Kansas Chapter of Us TOO sent me this follow-up to yesterday's post on Alpharadin. Interesting is this drug completed Phase II trials in Norway back in October 2007 involving 64 HRPC patients with more than twice as many patients receiving Alpharadin alive (10 of 33) two [...]

Algeta, Completing A Successful Phase II Trial For Men With Bone Metastases Will Begin Enrolling US Survivors Into A Phase III Trial

Algeta ASA (OSE: ALGETA), has announced that it will begin to enroll US survivors into its Alsympca phase III trial evaluating Alpharadin (radium-223). Alpharadin is designed to be used as a treatment for bone metastases in prostate cancer survivors with hormone-refractory prostate cancer (HRPC). The announcement of the trial follows a successful end-of-phase II meeting [...]

Go to Top